top of page

Cyclo Therapeutics Media Release | May 30, 2024

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Read the full statement from Cyclo Therapeutics here:

Here is a summary of the article:

For more information about the Company’s TransportNPC™ pivotal Phase 3 study, visit and reference identifier NCT04860960.


To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."

Ways to support NP-C in Australia:

25 views0 comments


Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page